查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1973924

抗肥胖药物市场分析及至2035年预测：类型、产品、服务、技术、组件、应用、剂型、最终用户、设备、模式

Anti Obesity Drugs Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Component, Application, Form, End User, Device, Mode
出版日期: | 出版商: Global Insight Services | 英文 331 Pages | 商品交期: 3-5个工作天内

价格
简介目录

预计到2034年，抗肥胖药物市场规模将从2024年的172亿美元成长至1,641亿美元，年复合成长率约为25.3%。该市场涵盖透过抑制食慾、促进新陈代谢和抑制脂肪吸收来帮助减重的药物。肥胖率上升、生活方式改变和健康意识增强是推动该市场成长的主要因素。注重疗效、安全性和减少副作用的创新，以及监管部门的核准，正在塑造市场动态。策略合作和研发投入对于解决全球肥胖问题至关重要，并蕴藏着巨大的成长机会。

受肥胖率上升和人们对健康风险意识增强的推动，抗肥胖药物市场正经历显着增长。药物治疗领域占据主导地位，其中GLP-1受体促效剂因其在体重管理和代谢改善方面的有效性主导。具有协同效应并能改善患者预后的复方药物紧跟其后。处方药细分市场表现优于非处方药，这得益于医师的推荐和已证实的临床结果。肠道菌群调节剂等新兴疗法作为新的减重方法正受到关注。针对儿童肥胖的儿童抗肥胖药物市场也预计将成长。药物递送系统的创新，包括口服和注射剂型，正在提高患者依从性并扩大市场吸引力。随着基于基因谱的个人化治疗策略的重要性日益凸显，个人化医疗也变得愈发重要。製药业持续的研发投入和策略合作正在推动市场扩张。

市场区隔
类型 处方药、非处方药、草药补充剂
产品 食慾抑制剂、代谢促进剂、脂肪吸收抑制剂、复方药物
服务 咨询服务、体重管理计划、生活方式指导
科技 药理基因体学、奈米技术、生物技术
成分 活性成分、添加剂
目的 慢性肥胖、体重管理
形式 片剂、胶囊、液体、注射剂
最终用户 医院、诊所、居家医疗机构、健康中心
装置 医疗设备、穿戴式装置
模式 口服，注射

市场概况：

随着多家公司推出创新产品，抗肥胖药物市场正经历市场份额的动态变化。定价策略依然竞争激烈，反映出市场对有效体重管理方案的需求。新产品的推出着重于先进的製剂技术和给药机制，从而提升了消费者的兴趣。市场正朝着个人化医疗的方向发展，各公司加大研发投入，致力于提供个人化解决方案。竞争基准分析凸显了主要企业利用策略联盟和收购来巩固其市场地位的主导地位。监管影响显着，严格的指导方针影响医药品认证过程。然而，这些法规也有助于确保药物的高安全性和有效性标准，并增强消费者信心。该市场的特点是技术快速发展，人工智慧和数据分析在药物研发中发挥着至关重要的作用。在全球范围内，北美和欧洲主导地位，而新兴市场则展现出尚未开发的成长潜力，不同地区的市场接受度也存在差异。

主要趋势和驱动因素：

受肥胖率上升和人们对健康风险意识增强的推动，抗肥胖药物市场正经历强劲增长。药物研发领域的技术创新使得疗效更佳、副作用更少的治疗方法成为可能，从而促进了市场扩张。生活方式的改变和久坐不动的生活方式加剧了肥胖的流行，因此需要药物干预。政府推行的促进体重管理和肥胖预防的措施和医疗保健政策进一步推动了市场发展。随着人们对个人化医疗的需求日益增长，标靶治疗的创新不断进步，提高了药物疗效和患者预后。此外，数位健康工具的整合有助于提高病患的用药依从性和监测效果，进而提高治疗成功率。在新兴市场，不断完善的医疗基础设施和不断增长的可支配收入创造了盈利的市场机会。製药公司之间的策略联盟和合作研究正在加速研发和新型抗肥胖药物的上市。随着人们对肥胖相关併发症的认识不断提高，预计该市场将继续成长，并专注于提供全面、以患者为中心的解决方案。

压制与挑战：

目前，抗肥胖药物市场面临许多重大限制与挑战。首要限制因素是严格的法规环境，繁琐的核准流程延缓了新药上市。这种监管复杂性往往导致製药公司成本增加、研发週期延长。另一个挑战是药物研发和商业化成本高昂，这会阻碍投资和创新。许多公司在尝试将新型抗肥胖解决方案推向市场时都面临资金障碍。此外，持续存在的社会歧视削弱了市场潜力，导致患者治疗顺从性降低，不愿寻求治疗。另外，现有抗肥胖药物疗效有限且副作用较大，也阻碍了市场发展，往往无法满足患者和医生的期望。最后，生活方式和饮食疗法作为第一线治疗方案的日益普及进一步降低了对药物治疗的需求，从而影响了市场成长。

目录

第一章执行摘要

第二章 市集亮点

第三章 市场动态

  • 宏观经济分析
  • 市场趋势
  • 市场驱动因素
  • 市场机会
  • 市场限制因素
  • 复合年均成长率：成长分析
  • 影响分析
  • 新兴市场
  • 技术蓝图
  • 战略框架

第四章：细分市场分析

  • 市场规模及预测：依类型
    • 处方药
    • 非处方药
    • 草药补充剂
  • 市场规模及预测：依产品划分
    • 食慾抑制剂
    • 代谢加速器
    • 脂质吸收抑制剂
    • 复方药物
  • 市场规模及预测：依服务划分
    • 咨询服务
    • 体重管理计划
    • 生活方式指导
  • 市场规模及预测：依技术划分
    • 药物基因体学
    • 奈米科技
    • 生物技术
  • 市场规模及预测：依组件划分
    • 医药原料药
    • 添加剂
  • 市场规模及预测：依应用领域划分
    • 慢性肥胖
    • 体重管理
  • 市场规模及预测：依类型
    • 药片
    • 胶囊
    • 液体
    • 注射药物
  • 市场规模及预测：依最终用户划分
    • 医院
    • 诊所
    • 居家医疗环境
    • 健康中心
  • 市场规模及预测：依设备划分
    • 医疗设备
    • 穿戴式装置
  • 市场规模及预测：按模式
    • 口服
    • 注射药物

第五章 区域分析

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲
  • 亚太地区
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲
    • 台湾
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利
    • 其他欧洲国家
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 撒哈拉以南非洲
    • 其他中东和非洲地区

第六章 市场策略

  • 供需差距分析
  • 贸易和物流限制
  • 价格、成本和利润率趋势
  • 市场渗透率
  • 消费者分析
  • 监管概述

第七章 竞争讯息

  • 市场定位
  • 市场占有率
  • 竞争基准
  • 主要企业的策略

第八章：公司简介

  • Orexigen Therapeutics
  • Vivus
  • Arena Pharmaceuticals
  • Zafgen
  • Rhythm Pharmaceuticals
  • Novo Nordisk
  • Gelesis
  • Eisai Co Ltd
  • Alizyme Therapeutics
  • NeuroSearch
  • Sorrento Therapeutics
  • Amgen
  • Allergan
  • Saniona
  • 8i Ventures

第九章 关于我们

简介目录
Product Code: GIS33623

Anti Obesity Drugs Market is anticipated to expand from $17.2 billion in 2024 to $164.1 billion by 2034, growing at a CAGR of approximately 25.3%. The Anti Obesity Drugs Market encompasses pharmaceuticals designed to aid weight loss by reducing appetite, increasing metabolism, or inhibiting fat absorption. This market is driven by rising obesity rates, lifestyle changes, and increasing health awareness. Innovations focus on efficacy, safety, and minimal side effects, with regulatory approvals shaping market dynamics. Strategic partnerships and research investments are pivotal in addressing the global obesity epidemic, offering significant growth opportunities.

The Anti-Obesity Drugs Market is experiencing significant growth, propelled by rising obesity rates and increased awareness of health risks. The pharmacotherapy segment dominates, with GLP-1 receptor agonists leading due to their efficacy in weight management and metabolic improvement. Following closely are combination drugs, which offer synergistic effects and enhanced patient outcomes. The prescription drugs sub-segment outperforms over-the-counter options, driven by physician recommendations and proven clinical results. Emerging therapies, such as gut microbiome modulators, are gaining attention for their novel approach to weight loss. The pediatric anti-obesity drugs segment is also expected to grow, addressing childhood obesity concerns. Innovations in drug delivery systems, including oral and injectable formulations, enhance patient compliance and broaden market appeal. Personalized medicine is becoming increasingly relevant, with genetic profiling guiding tailored therapeutic strategies. The market is poised for expansion, supported by ongoing research and development efforts and strategic partnerships in the pharmaceutical industry.

Market Segmentation
TypePrescription Drugs, Over-the-Counter Drugs, Herbal Supplements
ProductAppetite Suppressants, Metabolic Enhancers, Fat Absorption Inhibitors, Combination Drugs
ServicesConsultation Services, Weight Management Programs, Lifestyle Counseling
TechnologyPharmacogenomics, Nanotechnology, Biotechnology
ComponentActive Pharmaceutical Ingredients, Excipients
ApplicationChronic Obesity, Weight Management
FormTablets, Capsules, Liquid, Injectables
End UserHospitals, Clinics, Home Care Settings, Wellness Centers
DeviceMedical Devices, Wearable Devices
ModeOral, Injectable

Market Snapshot:

The Anti Obesity Drugs Market is experiencing a dynamic shift in market share, with several companies introducing innovative products. Pricing strategies remain competitive, reflecting the demand for effective weight management solutions. New product launches are focusing on advanced formulations and delivery mechanisms, contributing to heightened consumer interest. The market is witnessing a trend towards personalized medicine, with companies investing in research and development to offer tailored solutions. Competition benchmarking highlights the dominance of key players who are leveraging strategic partnerships and acquisitions to enhance their market position. Regulatory influences are significant, with stringent guidelines affecting drug approval processes. However, these regulations also ensure high safety and efficacy standards, fostering consumer trust. The market is characterized by rapid technological advancements, with AI and data analytics playing crucial roles in drug development. The global landscape shows varying adoption rates, with North America and Europe leading, while emerging markets present untapped potential for growth.

Geographical Overview:

The anti-obesity drugs market is witnessing notable growth across diverse regions, each exhibiting unique characteristics. North America dominates the market, propelled by escalating obesity rates and robust healthcare infrastructure. The region's focus on innovative drug development and supportive regulatory frameworks further bolsters its market leadership. Europe follows, driven by increasing health consciousness and government initiatives to curb obesity prevalence. The region benefits from a strong pharmaceutical industry and collaborative research efforts. In the Asia Pacific, the market is expanding rapidly, driven by rising obesity rates and increasing healthcare expenditure. Countries like China and India are emerging as significant growth pockets due to their large population base and improving healthcare access. Latin America and the Middle East & Africa are also witnessing growth, albeit at a slower pace. In these regions, rising awareness and government initiatives to combat obesity are creating new opportunities for market expansion.

Key Trends and Drivers:

The Anti-Obesity Drugs Market is experiencing robust growth fueled by rising obesity rates and increasing awareness of health risks. Technological advancements in drug development have led to more effective treatments with fewer side effects, driving market expansion. Lifestyle changes and sedentary habits are contributing to higher obesity prevalence, necessitating pharmaceutical interventions. Government initiatives and healthcare policies promoting weight management and obesity prevention are further propelling the market. The demand for personalized medicine is encouraging innovation in targeted therapies, enhancing drug efficacy and patient outcomes. Additionally, the integration of digital health tools is supporting patient adherence and monitoring, bolstering treatment success. Emerging markets present lucrative opportunities due to growing healthcare infrastructure and rising disposable incomes. Strategic partnerships and collaborations among pharmaceutical companies are fostering research and development, accelerating the introduction of novel anti-obesity drugs. As awareness of obesity-related complications increases, the market is poised for sustained growth, with a focus on holistic and patient-centric solutions.

Restraints and Challenges:

The Anti-Obesity Drugs Market is currently confronted with several significant restraints and challenges. A primary restraint is the stringent regulatory environment, which imposes rigorous approval processes, delaying the introduction of new drugs to the market. This regulatory complexity often results in increased costs and extended timelines for pharmaceutical companies. Another challenge is the high cost of drug development and commercialization, which can deter investment and innovation. Many companies face financial barriers when attempting to bring novel anti-obesity solutions to market. Additionally, there is a persistent stigma associated with obesity, leading to low patient adherence and reluctance to seek treatment, which undermines market potential. Moreover, the market is hindered by the limited efficacy and side effects of current anti-obesity medications, which often fail to meet patient and physician expectations. Lastly, the growing emphasis on lifestyle and dietary interventions as first-line treatments further diminishes the demand for pharmacological solutions, impacting market growth.

Key Players:

Orexigen Therapeutics, Vivus, Arena Pharmaceuticals, Zafgen, Rhythm Pharmaceuticals, Novo Nordisk, Gelesis, Eisai Co Ltd, Alizyme Therapeutics, NeuroSearch, Sorrento Therapeutics, Amgen, Allergan, Saniona, 8i Ventures

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Component
  • 2.6 Key Market Highlights by Application
  • 2.7 Key Market Highlights by Form
  • 2.8 Key Market Highlights by End User
  • 2.9 Key Market Highlights by Device
  • 2.10 Key Market Highlights by Mode

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Prescription Drugs
    • 4.1.2 Over-the-Counter Drugs
    • 4.1.3 Herbal Supplements
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Appetite Suppressants
    • 4.2.2 Metabolic Enhancers
    • 4.2.3 Fat Absorption Inhibitors
    • 4.2.4 Combination Drugs
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Consultation Services
    • 4.3.2 Weight Management Programs
    • 4.3.3 Lifestyle Counseling
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Pharmacogenomics
    • 4.4.2 Nanotechnology
    • 4.4.3 Biotechnology
  • 4.5 Market Size & Forecast by Component (2020-2035)
    • 4.5.1 Active Pharmaceutical Ingredients
    • 4.5.2 Excipients
  • 4.6 Market Size & Forecast by Application (2020-2035)
    • 4.6.1 Chronic Obesity
    • 4.6.2 Weight Management
  • 4.7 Market Size & Forecast by Form (2020-2035)
    • 4.7.1 Tablets
    • 4.7.2 Capsules
    • 4.7.3 Liquid
    • 4.7.4 Injectables
  • 4.8 Market Size & Forecast by End User (2020-2035)
    • 4.8.1 Hospitals
    • 4.8.2 Clinics
    • 4.8.3 Home Care Settings
    • 4.8.4 Wellness Centers
  • 4.9 Market Size & Forecast by Device (2020-2035)
    • 4.9.1 Medical Devices
    • 4.9.2 Wearable Devices
  • 4.10 Market Size & Forecast by Mode (2020-2035)
    • 4.10.1 Oral
    • 4.10.2 Injectable

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Component
      • 5.2.1.6 Application
      • 5.2.1.7 Form
      • 5.2.1.8 End User
      • 5.2.1.9 Device
      • 5.2.1.10 Mode
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Component
      • 5.2.2.6 Application
      • 5.2.2.7 Form
      • 5.2.2.8 End User
      • 5.2.2.9 Device
      • 5.2.2.10 Mode
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Component
      • 5.2.3.6 Application
      • 5.2.3.7 Form
      • 5.2.3.8 End User
      • 5.2.3.9 Device
      • 5.2.3.10 Mode
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Component
      • 5.3.1.6 Application
      • 5.3.1.7 Form
      • 5.3.1.8 End User
      • 5.3.1.9 Device
      • 5.3.1.10 Mode
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Component
      • 5.3.2.6 Application
      • 5.3.2.7 Form
      • 5.3.2.8 End User
      • 5.3.2.9 Device
      • 5.3.2.10 Mode
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Component
      • 5.3.3.6 Application
      • 5.3.3.7 Form
      • 5.3.3.8 End User
      • 5.3.3.9 Device
      • 5.3.3.10 Mode
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Component
      • 5.4.1.6 Application
      • 5.4.1.7 Form
      • 5.4.1.8 End User
      • 5.4.1.9 Device
      • 5.4.1.10 Mode
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Component
      • 5.4.2.6 Application
      • 5.4.2.7 Form
      • 5.4.2.8 End User
      • 5.4.2.9 Device
      • 5.4.2.10 Mode
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Component
      • 5.4.3.6 Application
      • 5.4.3.7 Form
      • 5.4.3.8 End User
      • 5.4.3.9 Device
      • 5.4.3.10 Mode
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Component
      • 5.4.4.6 Application
      • 5.4.4.7 Form
      • 5.4.4.8 End User
      • 5.4.4.9 Device
      • 5.4.4.10 Mode
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Component
      • 5.4.5.6 Application
      • 5.4.5.7 Form
      • 5.4.5.8 End User
      • 5.4.5.9 Device
      • 5.4.5.10 Mode
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Component
      • 5.4.6.6 Application
      • 5.4.6.7 Form
      • 5.4.6.8 End User
      • 5.4.6.9 Device
      • 5.4.6.10 Mode
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Component
      • 5.4.7.6 Application
      • 5.4.7.7 Form
      • 5.4.7.8 End User
      • 5.4.7.9 Device
      • 5.4.7.10 Mode
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Component
      • 5.5.1.6 Application
      • 5.5.1.7 Form
      • 5.5.1.8 End User
      • 5.5.1.9 Device
      • 5.5.1.10 Mode
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Component
      • 5.5.2.6 Application
      • 5.5.2.7 Form
      • 5.5.2.8 End User
      • 5.5.2.9 Device
      • 5.5.2.10 Mode
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Component
      • 5.5.3.6 Application
      • 5.5.3.7 Form
      • 5.5.3.8 End User
      • 5.5.3.9 Device
      • 5.5.3.10 Mode
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Component
      • 5.5.4.6 Application
      • 5.5.4.7 Form
      • 5.5.4.8 End User
      • 5.5.4.9 Device
      • 5.5.4.10 Mode
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Component
      • 5.5.5.6 Application
      • 5.5.5.7 Form
      • 5.5.5.8 End User
      • 5.5.5.9 Device
      • 5.5.5.10 Mode
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Component
      • 5.5.6.6 Application
      • 5.5.6.7 Form
      • 5.5.6.8 End User
      • 5.5.6.9 Device
      • 5.5.6.10 Mode
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Component
      • 5.6.1.6 Application
      • 5.6.1.7 Form
      • 5.6.1.8 End User
      • 5.6.1.9 Device
      • 5.6.1.10 Mode
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Component
      • 5.6.2.6 Application
      • 5.6.2.7 Form
      • 5.6.2.8 End User
      • 5.6.2.9 Device
      • 5.6.2.10 Mode
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Component
      • 5.6.3.6 Application
      • 5.6.3.7 Form
      • 5.6.3.8 End User
      • 5.6.3.9 Device
      • 5.6.3.10 Mode
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Component
      • 5.6.4.6 Application
      • 5.6.4.7 Form
      • 5.6.4.8 End User
      • 5.6.4.9 Device
      • 5.6.4.10 Mode
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Component
      • 5.6.5.6 Application
      • 5.6.5.7 Form
      • 5.6.5.8 End User
      • 5.6.5.9 Device
      • 5.6.5.10 Mode

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Orexigen Therapeutics
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Vivus
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Arena Pharmaceuticals
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Zafgen
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Rhythm Pharmaceuticals
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Novo Nordisk
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Gelesis
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Eisai Co Ltd
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Alizyme Therapeutics
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 NeuroSearch
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Sorrento Therapeutics
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Amgen
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Allergan
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Saniona
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 8i Ventures
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us